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Background: This study assessed the effects of inhaled corticosteroid (ICS) on airway vascular 
remodeling in chronic obstructive pulmonary disease (COPD).
Methods: Thirty-four subjects with mild-to-moderate COPD were randomly allocated 2:1 to 
ICS or placebo treatment in a double-blinded clinical trial over 6 months. Available tissue was 
compared before and after treatment for vessel density, and expression of VEGF, TGF-β1, and 
TGF-β1-related phosphorylated transcription factors p-SMAD 2/3. This clinical trial has been 
registered and allocated with the Australian New Zealand Clinical Trials Registry (ANZCTR) 
on 17/10/2012 with reference number ACTRN12612001111864.
Results: There were no significant baseline differences between treatment groups. With ICS, 
vessels and angiogenic factors did not change in hypervascular reticular basement membrane, but 
in the hypovascular lamina propria (LP), vessels increased and this had a proportionate effect on 
lung air trapping. There was modest evidence for a reduction in LP vessels staining for VEGF 
with ICS treatment, but a marked and significant reduction in p-SMAD 2/3 expression.
Conclusion: Six-month high-dose ICS treatment had little effect on hypervascularity or angio-
genic growth factors in the reticular basement membrane in COPD, but normalized hypovas-
cularity in the LP, and this was physiologically relevant, though accompanied by a paradoxical 
reduction in growth factor expression.
Keywords: airway remodeling, bronchial biopsy, COPD, inhaled corticosteroid, vascular 
remodeling
Introduction
Smoking and resulting chronic obstructive pulmonary disease (COPD) are major 
worldwide health problems.1 Previous insights into the details of airway remodeling 
in the airway wall in COPD have been quite limited, and our knowledge about the 
effects of inhaled corticosteroid (ICS) on such airway remodeling is even scantier.
We have reported some novel characteristics of airway remodeling using bronchial 
biopsies (BB) in COPD. For example, we found that the subepithelial reticular basement 
membrane (Rbm) was markedly fragmented and hypervascular (Figure 1), in asso-
ciation with increased vessel expression of angiogenic factors VEGF and TGF-β1.2–7 
Hiroshima et al8 have reported vessel growth up into the epithelium in COPD. These 
changes in combination are reminiscent of epithelial–mesenchymal transition (EMT) 
type-3, which is thought of as a procancerous condition.4,6,9
In contrast to the Rbm and epithelium, we described the subepithelial/sub-Rbm 
lamina propria (LP) as being hypovascular in current smokers with COPD.4,7
ICS has become standard treatment in more severe COPD, on the basis of empiri-
cal results from large multicenter studies.1,10,11 Studies have shown some limited 
clinical improvement, anti-inflammatory effects, and also changes in extracellular 
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matrix in airways with ICS treatment.11–16 Some positive 
effects on mortality and a protective effect of ICS on lung 
cancer development have also been reported in COPD.11,17–20 
The mechanisms of any lung (airway) cancer protection 
with ICS are not clear,20 although we have demonstrated, 
using airway biopsies, that ICS therapy improves EMT-
related changes.9,21
Our group has previously shown that ICS therapy has anti-
angiogenic effects in asthma.22 Therefore, we hypothesized 
that ICS may have similar antiangiogenic activity in COPD 
airways, as another potential cancer-protective effect.
Methods
Our human airway tissue material originated from a double-
blinded, randomized, and placebo-controlled clinical trial 
performed in 2000–2003 and involving 34 COPD subjects 
(Figure 2).9 After a 2-week run-in period, baseline assess-
ments of spirometry and fiberoptic bronchoscopy with BB 
A B
Rbm
Epithelium
20 µm 20 µm
Figure 1 rbm and lP vessels stained with anti-Collagen IV antibody in (A) and anti-Factor VIII antibody in (B). The epithelium sits on the basement membrane. 
The thickness of the rbm, is shown with the two-headed arrow. Vessels are in contact or embedded within the rbm (arrows). arrowheads indicate vessels in the lamina 
propria. Magnification ×400; scale bar =20 µm.
Abbreviations: rbm, reticular basement membrane; lP, lamina propria.
34 COPD subjects recruited
2-week running period;
assessment: including
lung function, bronchoscopy,
and biopsy
Randomization (2:1 active/placebo)
11 placebo ×6 months23 FP ×6 months
3 withdrew (side effects)
1 severe exacerbation
1 lack of adherence
1 subject refused 2nd
biopsy, 2 subjects
without enough tissue
Reassessment
after treatment
8 subjects18 subjects18 subjects
Number of subjects with enough
paired tissue for comparisons: FP/placebo
VEGF staining
16/7 8/3
Smad staining
8/3
TGF-β1 staining
13/6
Factor VIII
vessel staining
Figure 2 study subjects and design.
Abbreviations: FP, fluticasone propionate; COPD, chronic obstructive pulmonary disease.
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response of COPD airways to treatment
were undertaken. Then, using a computer-generated random-
numbers table, the participants were randomized 2:1 to 
receive fluticasone propionate (Accuhaler; Glaxo Wellcome, 
Middlesex, UK; 500 µg twice daily) or placebo for 6 months 
via an identical dry placebo inhaler. At the end of the treat-
ment period, lung function and BB were obtained again. The 
details of study design and data on inflammatory cell profiles 
have been published previously by our group.12 The study 
was approved by the Alfred and Royal Hobart Hospital Eth-
ics Committees. Unfortunately, because these tissues have 
already been depleted by previous analyses, the paired samples 
available for this study was rather limited (26 matching biopsy 
sets), but it still turned out to be highly informative.
subjects
All subjects gave written informed consent prior to participa-
tion. We included those who were older than 45 years with 
more than a 15 pack-year history of smoking. Subjects with a 
history suggestive of asthma, those who had used any steroids 
(oral or inhaled), or who had experienced an exacerbation of 
COPD within 12 weeks before recruitment were excluded. 
Other exclusion criteria included significant uncontrolled 
comorbidities such as diabetes, angina, or cardiac failure, and 
other coexisting respiratory disorders, including pulmonary 
fibrosis, lung cancer, and bronchiectasis.12,23 The diagnosis 
of COPD met Global initiative for chronic Obstructive Lung 
Disease physiological criteria.24
lung function
Spirometry, diffusing capacity of the lung for carbon monox-
ide, and lung volumes by body plethysmography were per-
formed according to American Thoracic Society/European 
Respiratory Society Task Force guidelines.25
Fiberoptic bronchoscopies
Bronchoscopies and biopsies were performed as previously 
described.4
Tissue processing and immunostaining
We used anti-Factor VIII antibody for staining of vessels 
in our samples because, as we reported previously, it is 
best at demonstrating newer vessels;7 we also undertook 
a preliminary evaluation of the effects of ICS on selected 
vascular growth factors in our biopsy tissues.
Details of tissue processing are available in our previously 
published paper.26 Briefly, following removal of paraffin and 
subsequent hydration, immunostaining for von Willebrand 
factor (Factor VIII-related antigen) (Dacocytomation, 
Copenhagen, Denmark; Dako M06160 1:150 for 90 minutes 
at room temperature, following heat retrieval using Dako 
S1699 for 20 minutes in a pressure cooker), VEGF (Fitzger-
ald, Concord, MA, USA; Catalog number 10R – V101ax: 
1/500 dilution, overnight at room temperature), anti-TGF-β1 
(Abcam, Cambridge, UK; abcam ab 27969 clone TB1 at 
1/16,000–6.25×10−5 mg/mL – overnight at room temperature 
after blocking with Dako serum block X0909; Dacocytoma-
tion), and p-Smad 2/3 (Santa Cruz SRC11769R incubated 
at 1/100 60 minutes at room temperature following heat 
retrieval using Dako PT link low PH – [K8005] for 30 min-
utes at 97°C) was performed on two 3.5 µm sections that 
were separated by 50 µm.
The primary antibody was elaborated using either anti-
mouse or anti-rabbit horseradish peroxidase conjugated 
DAKO Envision + reagent (K4001 or K4003) for secondary 
antibody binding and color resolution using Dako DAB+ 
(K3468). Nuclei were counterstained using Mayer’s Hema-
toxylin and sections dehydrated by using ascending grades 
of ethanol, cleared in xylene, and mounted in per mount. In 
each case, a nonimmune IgG1 negative control (X0931 clone 
DAK-GO1; Dacocytomation) was performed to eliminate 
false-positive staining, and endogenous peroxidase in tis-
sue was removed by incubation in a 3% hydrogen peroxide 
solution for 15 minutes prior to incubation with the primary 
antibody. A known lung tissue for positive tissue control was 
included with each staining.
Quantification of end points
Quantification of end points was performed before and after 
treatments with ICS or placebo using a computer-assisted 
image analysis (Leica DM 2500 microscope; Leica Micro-
systems, Wetzlar, Germany), a Spot insight 12 digital camera 
(Diagnostic Instruments, Inc., Sterling Heights, MI, USA), 
and Image Pro V5.1 (Media Cybernetics, Inc., Rockville, 
MD, USA) software. The details of measurements have 
been explained previously.4,6,7,26 All slides were coded and 
randomized by an independent person, and then counted 
by experienced observers (AS and SSS) blinded to subject, 
diagnosis, therapy, or sequence, with quality assurance on 
randomly selected slides provided by an academic clinical 
pathologist (HK).
Number of vessels in the Rbm were normalized by 
dividing by the length of Rbm (Figure 1). The number of 
vessels within the LP (Figure 1) was counted to a depth of 
150 µm, and vascular density was calculated two dimension-
ally. Vessels stained with VEGF and TGF-β1 in the Rbm 
were also quantified. As we reported previously, TGF-β1 
staining was heavy and diffused in the LP in most COPD 
samples and could not be adequately quantitated by this 
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immunohistological system,6,27 and so we substituted p-Smad 
2/3 expressions as an indicator of activity of the canonical 
intracellular TGF-β1 pathway.28
statistical analyses
At the time of developing this study, there were no data on 
which to base power calculation, and so we relied on previous 
precedent in similar asthma research, eg, Richmond et al’s29 
study which suggested numbers needed of around 12–15 per 
group, but also what was feasible in terms of volunteer recruit-
ment. In retrospect, using representative data from our control 
group, we can say that we did have 90% power at the 5% level 
to detect at least a 50% change in all our outcome measures 
at least within the active treatment group, but not between 
groups. The effect of interventions within groups was mea-
sured by comparing each outcome before and after treatment 
using the Wilcoxon’s two related-samples test, as the variables 
were non-normally distributed. Groups were compared using 
the Mann–Whitney test. Two-tailed P-values of 0.05 or less 
were considered as significant. For nominal variables, a χ2 test 
was used. Correlations were tested with Spearman’s correla-
tion analyses. All the statistical analyses were done using SPSS 
16.0 (IBM Corporation, Armonk, NY, USA).
Results
The demographics of the study groups are presented in Table 1, 
and for contextual contrast, some comparisons are made with 
the normal control group from a comparable previous study.7 
There were no significant differences between the two treat-
ment COPD groups in demographics, or in lung function, or 
in airway pathological indices of interest before interven-
tion (Tables 1 and 2) (see Figure 1 and Figures S1 and S2). 
Thirty-four COPD subjects initially participated, but not all 
could be represented in these analyses. Figure 2 summarizes 
the final number of subjects with adequate paired tissue for 
each immune stain; as might be expected, the demographics 
and other baseline data for this specifically included group of 
volunteers were very similar on average to the whole group.
Vessels in the rbm
Vessel number in the Rbm did not change significantly with 
ICS (Table 3). This also applied to current smokers who 
showed this signal most markedly.
Vessels in the lP
Overall, there was moderate evidence for an overall increase 
in vascular density with ICS (Table 3 and Figure 3). 
Table 1 Demographics of the study groupsa
Groups (numbers) ICS (n=23) Placebo (n=11) Normal nonsmoking 
control (n=8)
age, years 61 (46–69) 61 (52–69) 54 (32–68)
Female/male 9/14 4/7 2/6
Current smoker/ex-smoker 13/10 4/7 na
Pack-year smoking history 44 (18–150) 51 (22–148) 0
gOlD stage I/II 12/11 5/6 na
FeV1/FVC ratio 59 (41–68) 57 (38–68) 79 (71–88)
b
%DlCO predicted 65 (44–87) 66 (45–90) –
TlC, l 7.6 (5.3–8.4) 6.2 (5.1–9.8) –
rV, l 2.8 (2.1–4.0) 2.4 (1.6–4.7) –
Notes: Data from a normal control group have been added to this table from a comparable previous study. adapted from soltani a, Wood-Baker r, sohal ss, Muller hK, 
reid D, Walters eh. reticular basement membrane vessels are increased in COPD bronchial mucosa by both factor VIII and collagen IV immunostaining and are hyperpermeable. 
J Allergy (Cairo). 2012:958383. Creative Commons license and disclaimer available from: http://creativecommons.org/licenses/by/4.0/legalcode.7 This additional material was 
used for the comparison made in Figure 3 between normal controls and both treatment groups before and after interventions. aall data in the table are presented as median 
(range); bsignificantly different between normal controls and COPD groups. “–”, no data.
Abbreviations: DlCO, diffusion capacity of lung diffusion for carbon monoxide; FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity; gOlD, global 
initiative for chronic Obstructive lung Disease; ICs, inhaled corticosteroid; na, not applicable; rV, residual volume; TlC, total lung capacity.
Table 2 Comparison of baseline tissue vascular parameters between groupsa
Groupsb ICS Placebo P-values
no of rbm vessels/mm rbm 5.1 (0.0–15.2) 3.6 (1.8–6.5) 0.5
no of vessels in the rbm stained for VegF/mm rbm 0.6 (0.0–5.4) 1.0 (0.0–5.4) 0.9
no of vessels stained for TgF-β1/mm rbm 1.3 (0.0–8.1) 2.5 (0.7–4.0) 1.0
Density of lP vessels number/mm2 289 (158–585) 277 (200–641) 0.7
no of vessels stained for VegF in the lP/mm2 113 (21–276) 144 (16–366) 0.5
Notes: also see Figure 1 and Figures s1 and s2. aall data in the table are presented as median (range); bnumbers of subjects for ICs vs placebo for Factor VIII vessel staining 
were 13 vs 6; for VegF staining 16 vs 7; and for TgF-β1 staining 8 vs 3.
Abbreviations: ICs, inhaled corticosteroid; lP, lamina propria; rbm, reticular basement membrane.
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response of COPD airways to treatment
Furthermore, in the current smoking COPD subgroup, where 
the LP was most markedly hypovascular at baseline, there 
was even stronger evidence for a normalization of vessels 
(median [range] 219 [158–437] before vs 356 [213–413] 
after ICS, P=0.05). This was also well illustrated when we 
performed a regression of change in vessel number with base-
line vessel number in the LP (Figure 4): there was a negative 
correlation between the baseline number of vessels in the LP 
and the changes with treatment in the whole COPD group 
(r=−0.7, P0.01) and also in the current smoking subgroup 
alone (r=−0.7, P=0.05). Thus, vessels increased in density 
with ICS mainly in those subjects most hypovascular, and 
especially in those below the median in the nonsmoking 
controls (ie, 408/mm2 of the LP, Figure 3). Above this cutoff, 
there was essentially no change in vessel number with ICS, 
suggesting that there was not merely a regression toward the 
mean across the range.
VegF, TgF-β1, and p-sMaD 2/3 in the  
rbm
The percentage of vessels stained for VEGF in the Rbm did 
not change with either treatment (Table 3), nor was there any 
effect of ICS treatment for percentage of vessels stained for 
TGF-β1. There was little suggestion for any change in the 
placebo group (median 93% before vs 79% after intervention; 
P=1.00), though the number of pairs of tissues was too small 
for formal analysis (Figure 2). There was modest evidence 
(given the numbers involved) for a decrease in percentage 
Table 3 Changes with treatmenta
Measurements ICS Placebo
Before After P-values Before After P-values
number of rbm vessels/mm rbm 5.1 (0.0–15.2) 2.3 (0.8–13) 0.5 3.6 (1.8–6.5) 2.8 (1.3–10.8) 0.9
number of lP vessels/mm2 of lP 289 (158–585) 386 (213–444) 0.08 277 (200–641) 295 (173–377) 0.5
% of vessels stained for VegF/mm rbmc 19% (0–256) 16% (0–302) 0.5 0% (0–49) 19% (0–250) 0.9
% of vessels stained for TgF-β1/mm rbmb,c 47% (0–154) 94% (0–1,416) 0.3 – – –
% of vessels stained for p-smad 2/3/mm rbmb,c 69% (46–119) 0% (0–89) 0.1 – – –
% of vessels stained for VegF/mm2 of lPc 61% (7–90) 35% (0–130) 0.2 32% (5–180) 88% (26–256) 0.3
% of vessels stained for p-smad 2/3/mm2 of lPb,c 24% (4–80) 10% (5–43) 0.03 – – –
TlC 7.6 (5.3–8.4) 7.6 (5.2–8.2) 0.4 6.2 (5.1–9.8) 6.3 (5.8–9.4) 0.5
rV 2.8 (2.1–4.0) 2.8 (2.0–4.2) 0.7 2.4 (1.6–4.7) 2.6 (2.1–4.5) 0.4
Notes: aall data in the table are presented as median (range); bsome cells do not contain numbers because the number of paired tissues was too small for formal analysis 
(the number of paired tissues for TgF-β1 and sMaD 2/3 in the placebo arm was three;); cpercentage of vessels stained for VegF/millimeter rbm, percentage of vessels 
stained for TgF-β1/mm rbm, percentage of vessels stained for p-sMaD2/3/mm rbm, percentage of vessels stained for VegF/mm2 of lP, and percentage of vessels stained for 
p-sMaD 2/3/mm2 of lP are calculated as vessels stained for VegF, TgF-β1, p-sMaD 2/3×100/total number of vessels stained for Factor VIII per mm of the rbm or per mm2 
of LP, respectively. Also see Figure 1 and Figures S1 and S2. “–”, no data.
Abbreviations: ICs, inhaled corticosteroid; lP, lamina propria; rbm, reticular basement membrane; TlC, total lung capacity; rV, residual volume.
Anti-Factor VIII antibody
ICS
P=0.08
Before BeforeAfter After H-N
1,000
800
600
400
200
0
Placebo
P=0.5
N
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P
Figure 3 The effects of ICs or placebo on lP vessels. The box plot of h-n shows 
that the lP was hypovascular in both treatment groups. Bars indicate medians. Dots 
and triangles represent current smoking and ex-smoking COPD subjects. There 
was strong trend for an increase in vessels overall, but this was confined to active 
smokers in whom the change was significant (P=0.05).
Abbreviations: lP, lamina propria; h-n, healthy nonsmokers; ICs, inhaled 
corticosteroid; COPD, chronic obstructive pulmonary disease.
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Figure 4 Significant correlation between the baseline number and change in LP 
vessels with ICS (fluticasone propionate) (r=−0.7, P=0.01). Circles and triangles 
present current smoking and ex-smoking COPD subjects, respectively.
Abbreviations: lP, lamina propria; ICs, inhaled corticosteroid; COPD, chronic 
obstructive pulmonary disease.
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of vessels stained for p-SMAD 2/3 in the Rbm with ICS. 
The number of data points in the placebo arm (n=3 paired 
slides) was too small for formal analysis, but there was little 
suggestion of any change.
VegF and p-sMaD 2/3 in the lP
There was little convincing evidence for a real change in 
percentage of VEGF-stained vessels with ICS although the 
numbers fell (Table 3). However, there was a more definite 
decrease in the percentage of p-SMAD 2/3-positive vessels 
with ICS treatment. Again, there was little suggestion of 
change in the placebo arm, but numbers available with both 
stains per individual were very small.
relation with lung function
There were strong negative correlations between changes 
of LP vessels and changes in residual volume (r=−0.8, 
P0.05) and between changes in total lung capacity (r=−0.9, 
P0.01) and ICS treatment in the current smoking COPD 
subgroup.
Discussion
This study, to our knowledge, is the first double-blinded 
placebo-controlled trial examining the effects of ICS on 
vascular remodeling in COPD airways. We made some poten-
tially important observations that were reasonably robust:
•	 ICS had no effect on vessel numbers, nor on angiogenic 
factor expression in the Rbm, though there was some 
suggestive evidence that p-SMAD 2/3 expression was 
attenuated.
•	 ICS normalized the low number of vessels in the LP, and 
this was associated with, rather paradoxically perhaps, 
some evidence for a decrease in VEGF and more definite 
evidence for decreased p-SMAD 2/3 expressions.
•	 Physiological indices of air trapping showed negative 
correlations with increased vessel numbers, ie, more 
vessels, less air trapping.
A previous report demonstrated the effectiveness of ICS 
in decreasing Rbm fragmentation and markers of EMT.9,21,27 
This current study has evaluated the effects of ICS on airway 
vascular remodeling in COPD and revealed that, in contrast to 
our hypothesis, hypervascularity of the Rbm did not respond 
to ICS treatment.
In contrast, this study found that, especially in the 
current smoking COPD group, ICS increased the density 
of LP vessels back to normal. This finding was not seen 
in the ex-smoking COPD subgroup, but vessel numbers 
here at baseline were essentially normal.4,7 These findings, 
accompanied by little change or indeed reduction in growth 
factor activity, may suggest that ICS reduced vessel destruc-
tion rather than promotion of new vessels. However, this 
does not easily fit with our previous observation in COPD 
airways of a switch from older to newer vessels.7 An alter-
native explanation could be that there was up-modulation 
of growth factor receptors on endothelial cells, as occurs 
in asthmatics on ICS,30 ie, making them more sensitive to 
growth factors.
Increase of LP vessels may have physiological sig-
nificance perhaps through increasing airway stiffness, thus 
reducing expiratory dynamic airway compression and con-
sequent air trapping.
A previously published “cross-sectional” study by Zanini 
et al13 compared bronchial tissues from ex-smokers with 
COPD who were treated with ICS to those who were not. 
Paradoxically, this study found increased vascularity in the 
COPD group that was not on ICS, suggesting an antiangio-
genic effect of ICS. Why their conclusions are different to 
ours is not easy to tell, but it is notable that we have not found 
vessel changes to be as marked in ex-smokers with COPD as 
in current smokers.4,7 Furthermore, a cross-sectional study is 
not as robust as a longitudinal one.
Limitations
One important “limitation” of our study was its quite selective 
choice of the angiogenic factors studied. This is potentially a 
hugely complex area with very many pro- and antiangiogenic 
factors that could be in play, including collagen breakdown 
products such as tumstatin, which is an angiogenic inhibitor 
said to be absent in asthma airways.31,32 But a comprehensive 
survey would be logistically very difficult, and one at least 
needs to start with the likely main players gleaned from the 
literature. In previous studies, we assessed the associations 
of VEGF and TGF-β1 with vessel changes in the airway sub-
epithelial Rbm in smokers and COPD subjects and showed 
increased activity of both angiogenic factors in hypervascular 
Rbm, a relationship between VEGF and lung function, and 
a correlation between TGF-β1 and total number of vessels 
in this compartment.4,6,7 VEGF is the most potent vascular 
growth factor, and its level is increased in chronic inflam-
mation, including in airway inflammation in asthma and 
smokers.8,30,33,34 TGF-β1 is a multifunction cytokine with 
angiogenic activity, the level of which is increased in airways 
in smokers and COPD.6,34 In addition, TGF-β1 receptors play 
an important role in the pathogenesis of COPD through their 
regulation of Smad pathways.35 A second major problem was 
limitation of paired biopsies from before and after treatment, 
mainly in the placebo treatment arm. This was partly due to 
the original 2:1 treatment allocation and because this study 
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was dependent on “remnants” of tissues not already used in 
a number of previous cellular and remodeling analyses. We 
always intended looking at vessel changes, and indeed, the 
signals that we have picked up as significant seem important 
and quite striking, in spite of these limitations.
Conclusion
In summary, this longitudinal, repeat bronchoscopy study, 
for the first time has attempted an evaluation of the effects 
of ICS on airway vessel remodeling in COPD. LP, but not 
Rbm vessels, seem responsive to treatment, with an increase 
in younger vessels stained with anti-Factor VIII antibody. 
Our physiological data suggest that increases in LP vessels 
decrease air trapping, perhaps because of resulting stiffer 
airways that can better resist expiratory dynamic airway 
compression.
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Supplementary materials
Rbm Epithelium 20 µm
Figure S1 VegF-stained vessels in the rbm and lP are pointed out with narrow arrows and wide arrows, respectively.
Notes: The lamina propria is situated beneath the Rbm. The width of the Rbm is shown by a two-headed arrow. Magnification ×400.
Abbreviations: rbm, reticular basement membrane; lP, lamina propria.
Rbm
Epithelium
20 µm
Figure S2 TgF-β-stained vessels in the rbm are pointed out with arrows. The generalized dark immunostaining in the lamina propria, which is situated beneath the rbm, 
impedes vessel identification. The width of the Rbm is shown by a two-headed arrow. Magnification ×400.
Abbreviation: rbm, reticular basement membrane.
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